Kezar Life Sciences, Inc.
7 clinical trials · Sponsor
◉ Watch Kezar Life Sciences, Inc.
| Record | Firm | Date |
|---|---|---|
| A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE) (NCT05781750) | Kezar Life Sciences, Inc. | 2023-11-03 |
| A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA) (NCT05569759) | Kezar Life Sciences, Inc. | 2023-05-23 |
| KZR-261 in Subjects With Advanced Solid Malignancies (NCT05047536) | Kezar Life Sciences, Inc. | 2021-09-30 |
| Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM. (NCT04628936) | Kezar Life Sciences, Inc. | 2020-11-04 |
| A Phase 2 Study to Evaluate the Safety and Efficacy of KZR-616 in Patients With AIHA and ITP (NCT04039477) | Kezar Life Sciences, Inc. | 2020-07-01 |
| A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis (NCT04033926) | Kezar Life Sciences, Inc. | 2020-01-14 |
| A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis (NCT03393013) | Kezar Life Sciences, Inc. | 2018-02-20 |
Track Kezar Life Sciences, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.